Amlogenyx
Amlogenyx, a subsidiary of Ultragenyx Pharmaceutical, Inc., focuses on researching and developing new gene therapies for Alzheimer’s disease and other amyloid-related conditions.
Launch date
Employees
Market cap
-
Enterprise valuation
€51—76m (Dealroom.co estimates Aug 2024.)
Somerville Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
* | $14.0m | Seed | |
| Total Funding | €12.7m | ||